NeuroGenesis Ltd. is advancing NG01, an autologous cell therapy, through a Phase 2b clinical trial aimed at addressing unmet needs in SPMS, a progressive form of multiple sclerosis with limited treatment options. The trial's design includes a randomized, double-blind, placebo-controlled approach, which enhances the credibility of potential efficacy claims. If successful, NG01 could capture a significant share of the SPMS market, which is currently underserved. The trial's outcomes may position NeuroGenesis favorably against competitors in the regenerative medicine space, particularly those focusing on neurological disorders. However, the company must navigate the complexities of regulatory approval and reimbursement pathways for cell therapies, which could impact market entry timelines and pricing strategies.